The article describes the challenging scenario of a severe bullous pemphigoid (BP) in a patient with chronic kidney failure, a major comorbid disease limiting the standard therapeutical approach. Here, tralokinumab led to the remission of BP after 8 weeks of treatment.
Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease / Roberto Maglie, Maria Efenesia Baffa, Stefano Senatore, Carlo Pipitò, Marzia Caproni, Farzan Solimani, Emiliano Antiga. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 1365-2230. - ELETTRONICO. - (2023), pp. 0-0.
Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease
Roberto Maglie
;Maria Efenesia Baffa;Stefano Senatore;Carlo Pipitò;Marzia Caproni;Emiliano Antiga
2023
Abstract
The article describes the challenging scenario of a severe bullous pemphigoid (BP) in a patient with chronic kidney failure, a major comorbid disease limiting the standard therapeutical approach. Here, tralokinumab led to the remission of BP after 8 weeks of treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
